Drug Trial Radar · NCT07507838
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 13, 2026
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation trial to assess the safety, tolerability, pharmacokinetics (PK) of multiple doses of VV913 in Chinese healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
VV913 4mg groupDrug
6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.
VV913 8mg groupDrug
6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.
VV913 15mg groupDrug
6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: Baseline to 6 days after the last administration
- CmaxTime frame: Baseline to 72 hours after the last administration
- AUC0-∞Time frame: Baseline to 72 hours after the last administration
- TmaxTime frame: Baseline to 72 hours after the last administration
- t1/2Time frame: Baseline to 72 hours after the last administration
- Apparent Clearance Rate(CL/F)Time frame: Baseline to 72 hours after the last administration
- Vd/FTime frame: Baseline to 72 hours after the last administration
- λzTime frame: Baseline to 72 hours after the last administration
- AUC0-24hTime frame: Baseline to 72 hours after the last administration
- mean Resident TimeTime frame: Baseline to 72 hours after the last administration
- RacTime frame: Baseline to 72 hours after the last administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.